Trial Profile

A phase 2, double-blind, double-dummy, randomised, parallel group dose finding study to investigate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation and to compare the safety and tolerability with warfarin.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Apr 2012 EudraCT reports actual initiation date as 28 May 2009.
16 Nov 2011 Planned number of patients changed from 1280 to 1320 as reported by European Clinical Trials Database.
28 Jul 2011 Results of an analysis of the effects of treatment on thrombogenesis markers presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com